Wegovy and Mounjaro These two products are frequently mentioned by people looking to lose weight these days. Reviews in online groups show amazing results, with many people experiencing rapid weight loss. However, choosing the right one can be confusing. What are the differences? Which one is more effective? How much does it cost? And what are the side effects? Everyone's body is different. Today, we'll compare them clearly to help you decide which one is right for you.
Main Idea
- Mounjaro (Tirzepatide) is an American weight-loss pen classified as a dual agonist. It works by mimicking the hormones GLP-1 and GIP simultaneously, helping you feel fuller for longer without dieting. It controls hunger, increases fat metabolism efficiency, improves insulin and metabolic systems, and can lead to weight loss of more than 15-20% or even more.
- Wegovy (Semaglutide) mimics the action of the hormone GLP-1, which stimulates insulin secretion to control blood sugar, inhibits glucagon (which increases blood sugar), and slows digestion, leading to faster and longer-lasting satiety, reducing appetite, and stimulating fat metabolism. This results in an average weight loss of around 15% or more.
- Wegovy and Mounjaro differ in aspects such as active ingredients, mechanism of action, average weight loss results, effect on blood sugar/HbA1c levels, and average price.
- Wegovy and Mounjaro cannot be administered together because their mechanisms of action overlap, increasing the risk of serious side effects and hypoglycemia.
Mounjaro slimming pen
Mounjaro The drug's trade name is "Tirzepatide." It's a weight-loss pen manufactured by Eli Lilly & Co. of the United States. It belongs to the group of dual agonists that mimic the action of two natural hormones: GLP-1 (Glucagon-like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide). This promotes a feeling of fullness without dieting, helps control hunger, improves fat metabolism, enhances insulin function, and regulates metabolism. After injection, it can lead to weight loss of more than 15% – 20% or even more.
Wegovy weight loss pen
Wegovy, or its trade name "Semaglutide," mimics the action of the hormone GLP-1 (Glucagon-Like Peptide-1). GLP-1 stimulates insulin secretion, which controls blood sugar levels. Wegovy, however, inhibits the release of glucagon, which increases blood sugar. It slows the passage of food through the stomach, resulting in longer-lasting satiety and reduced appetite. It also stimulates fat metabolism and can lead to weight loss of approximately 151 TP3T or possibly more.
What can Wegovy & Mounjaro help you with?
Wegovy mimics the action of the hormone GLP-1 (Glucagon-Like Peptide-1), thus helping to reduce appetite and curb snacking. It slows down gastric contractions, resulting in a longer feeling of fullness and can lead to weight loss of approximately 151 TP3T or more. Additionally, it may help reduce the risk of insulin resistance and cardiovascular disease.
Mounjaro mimics the action of two natural hormones, GLP-1 (Glucagon-like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide), simultaneously. This helps control hunger, improves metabolic efficiency, regulates metabolism, and can lead to weight loss of more than 15% – 20% or even more. It also helps control blood sugar levels for patients with type 2 diabetes.
Similarities between Wegovy and Mounjaro
Wegovy and Mounjaro are weight-loss pens with different active ingredients, but they also share some similarities, as follows:
- Mechanism of action: Wegovy and Mounjaro work by mimicking GLP-1 (Glucagon-like Peptide-1), a natural hormone released by the body after eating. This results in a longer feeling of fullness, reduces appetite, and decreases snacking, as well as slowing down gastric contractions.
- Goals of treatment and expected outcomes: Both types help reduce weight and fat mass. Additionally, they help control blood sugar levels and lower the risk of chronic diseases such as high blood pressure, dyslipidemia, and insulin resistance.
- Usage: Both types of weight-loss pens are injected subcutaneously, such as into the abdomen, thighs, or upper arms, only once a week.
- Increasing the dosage: Wegovy and Mounjaro will start with the lowest dose in the first month, then gradually increase the dose every 4 weeks to allow the body to adjust and reduce the chance of side effects.
- Side effects: Because both drugs act through the gastrointestinal system, common side effects include nausea, vomiting, constipation, diarrhea, bloating, abdominal discomfort, and food-smelling belches.
- Prohibited: Do not use in individuals with a history, or a family history, of medullary thyroid cancer (MTC) or MEN 2 endocrine disorder.
The difference between Wegovy and Mounjaro
Wegovy and Mounjaro both have properties that help reduce appetite, promote a feeling of fullness for longer periods, and delay gastric contractions. However, they also have differences, as shown in the table below.
| Comparison topics | Wegovy | Mounjaro |
| Active ingredient | Semaglutide | Tirzepatide |
| Mechanism of operation | It mimics the action of the hormone GLP-1 alone. | It mimics the hormones GLP-1 and GIP simultaneously. |
| Average weight loss results. | Reduce average body weight by 15%. | Reduce average body weight by 15-20%. |
| Effects on blood sugar/HbA1c levels. | Reduce HbA1c by approximately 1-21 TP3T. | It reduces HbA1c by approximately 2-2.41 TP3T (better results because it also acts through GIP). |
| Average price | Approximately 15,000 – 30,000 baht | Approximately 13,000 – 25,000 baht |
Can WeGovernment and Mounjaro be administered together?
Wegovy and Mounjaro cannot be administered together or simultaneously. Because both drugs act on the same GLP-1 hormone receptor, injecting them together does not lead to faster weight loss or a double dose of results. In fact, it may lead to an overdose. Furthermore, it may increase the risk of serious gastrointestinal side effects such as severe nausea, vomiting, and diarrhea that can lead to dehydration, as well as the risk of acute pancreatitis and hypoglycemia.
Which summary is right for whom?
For individuals considering using a weight-loss pen, please note that your weight loss goal is to lose no more than 15%, or you may be overweight and have weight-related comorbidities such as... High blood pressure Diabetes or high cholesterol. Wegovy It is considered a suitable and approved option for obesity, but if you have severe obesity, insulin resistance, or need to lose more than 15-20%, Mounjaro This is a more targeted option and can yield clearer results.
